CD274 and hepatocellular carcinoma: Given the differences of the two signals, combination of anti-CTLA4 and anti-PD-1/PD-L1 antibodies is reasonable and approved by US FDA in melanoma, but evidence is lacking for the combinatory use of ICIs in HCC.